The use of single-analyte biomarkers (e.g., PD-L1 expression) has yielded modest results in the quest to accurately predict which patients are likely to respond (or not) to immunotherapies and their combinations with other treatment modalities. In the immunotherapy age, it’s clear that more effective patient stratification techniques will require the integration of multiple biomarkers that not only molecularly profile a given patient’s tumor, but that also reveal how the host’s immune system is reacting to – and interacting with – that tumor.
At Personalis, we believe that such an approach will deliver the benefits of the immuno-oncology revolution to a greater proportion of patients. With the comprehensive tumor- and immune-related biomarker information that’s generated by ImmunoID NeXT, we can help our biopharmaceutical partners identify composite biomarkers to improve upon the predictive power of single-analyte approaches and bring the potential of immunotherapy to more cancer patients. NEOPS™ (Neoantigen Presentation Score) is an example of how this approach is able to drive more accurate biomarkers. By accounting for tumor escape mechanisms and combining them into a composite neoantigen score, NEOPS provides a fuller representation of tumor antigen presentation to the immune system compared to simpler models. Further, NEOPS can also be clinically practical, with comprehensive tumor profiling achieved using very limited tumor tissue.